Clinical Trials Sponsored by Pierre Fabre Laboratories

Total 155 results

Pfizer
Pierre Fabre Laboratories

Active, not recruiting

Pharmacokinetic Drug-drug Interaction Study of Encorafenib and Binimetinib on Probe Drugs in Patients With BRAF V600-mutant Melanoma or Other Advanced Solid Tumors

Advanced Solid Tumors | Metastatic Melanoma

United States, Spain, Belgium, Canada, Netherlands
Pfizer
Pierre Fabre Laboratories

Terminated

Study of the Combination of Binimetinib and Encorafenib in Adolescent Patients With Unresectable or Metastatic BRAF V600-mutant Melanoma

Melanoma

Italy
ARCAGY/ GINECO GROUP
Pierre Fabre Laboratories

Terminated

Addition of Aromatase at the Navelbine in Pretreated Metastatic Breast Cancer. (CHEOPS)

Breast Cancer

France
University of Aarhus
Pierre Fabre Laboratories

Completed

Phase II Trial With Metronomic, Capecitabine Plus Oral Vinorelbine for Metastatic Breast Cancer (XeNa)

Breast Cancer

Denmark
University of Lausanne
Pierre Fabre Laboratories

Completed

Clinical Evaluation of Iron Treatment Efficiency Among Non-anemic But Iron-deficient Female Blood Donors (ferdon)

Fatigue | Iron Deficiency

Switzerland
University Hospital, Limoges
Pierre Fabre Laboratories

Completed

Concomitant Radio-chemotherapy in the Elderly (RACCOSA)

Non Small Cell Lung Cancer

France
Pierre Fabre Medicament
Pierre Fabre Pharma GmbH

Completed

Oral Chemotherapy And Platinum With Radiotherapy Followed Or Not By Consolidation With The Same Chemotherapy In Locally Advanced Non Small Cell Lung Cancer

NSCLC

Germany
Pierre Fabre Medical Devices

Completed

Xerotic Dermatitis in Aged People

Itching Symptoms | Xerotic Dermatitis

France
Leiden University Medical Center
Pierre Fabre Laboratories

Recruiting

(Neo)Adjuvant BRAF/MEK Inhibition in pN1c Melanoma

Melanoma Stage III | In-Transit Metastasis of Cutaneous Melanoma

Netherlands
Wales Cancer Trials Unit
Pierre Fabre Laboratories

Completed

Vinorelbine in Mesothelioma (VIM)

Mesothelioma

United Kingdom
University Hospital, Clermont-Ferrand
Pierre Fabre Laboratories

Unknown

Eradication of Residual Disease by Preemptive Immunointervention After Allogeneic Hematopoietic Stem Cells Transplantation in Chronic Lymphocytic Leukemia (RICAC)

Chronic Lymphocytic Leukemia | Lymphocytic Lymphoma

France
Pierre Fabre Pharma GmbH
Pierre Fabre Pharma Austria; Pierre Fabre Pharma AG

Recruiting

Binimetinib Plus Encorafenib Real Life Investigation of Next Generation Melanoma Treatment (BERING)

Melanoma Stage IV | Melanoma Stage III

Austria, Germany, Switzerland
Pierre Fabre Medicament

Recruiting

A Prospective Observational Study on Targeted Therapy for Unresectable or Metastatic BRAFV600E Mutant Melanoma Patients (TavieSkin)

Metastatic Melanoma | Melanoma (Skin) | BRAF V600 Mutation

Portugal
Pierre Fabre Medicament

Completed

Study of Oral Vinorelbine Plus Capecitabine Versus Taxane-gemcitabine Combinations as 1st Line Chemotherapy in Metastatic Breast Cancer

Breast Cancer
Pierre Fabre Medicament

Active, not recruiting

A Study of a New Investigational Medicinal Product to Treat Patients With Advanced or Metastatic Solid Tumors (Ulysse)

Advanced or Metastatic Solid Tumors

France, Spain
Pierre Fabre Medicament

Completed

Trial of Vinflunine Versus Alkylating Agent in Metastatic Breast Cancer

Breast Cancer | Metastases

France, Ukraine, United Kingdom, Germany, Taiwan, Spain, Belarus, Belgium, Portugal, South Africa, Russian Federation, Austria, Italy, Argentina
Pierre Fabre Medicament

Completed

Efficacy and Safety Study of F373280

Atrial Fibrillation

Spain, Hungary, Italy, Poland, Czechia
Pierre Fabre Medicament

Completed

CLEARI (Clinical Efficacy Assessment on Recurrent Upper-Respiratory Tract Infections) Study

Recurrent Upper-Respiratory Tract Infections

Italy, Poland, Romania, Russian Federation, Lithuania
Pierre Fabre Medicament

Terminated

Ferrous Sulphate Supplement (V0355) in Women With Iron Deficiency Anaemia

Iron Deficiency Anemia

Bulgaria, Romania
Pierre Fabre Medicament

Completed

JAVLOR Association Study in CDDP-unfit Patients With Advanced Transitional Cell Carcinoma: Gemcitabine Versus Carboplatin (JASINT1)

Bladder Transitional Cell Carcinoma Stage IV

France
Pierre Fabre Medicament

Completed

Assessment of V0018 2.5 mg Effect on Craving

Healthy Highly Dependant Smokers

France
Pierre Fabre Medicament

Completed

Effect of F2695 on Functional Recovery After Ischemic Stroke (LIFE)

Ischemic Stroke

Spain, France, Switzerland, Germany, Sweden, Italy, Czech Republic, Portugal, Belgium, Hungary, Russian Federation
Pierre Fabre Dermatology

Completed

Study in Infants With Infantile Hemangioma to Compare Propranolol Gel to Placebo

Infantile Hemangioma

Spain, France, Poland
Pierre Fabre Medicament

Completed

Effect of V0251 in Acute Vertigo

Acute Vertigo

Spain, France, Germany, Czech Republic, Hungary
Pierre Fabre Medicament

Completed

Ibuprofen Lozenge in Acute Sore Throat Pain

Acute Sore Throat Pain

United Kingdom, Germany, Latvia, France
Pierre Fabre Dermatology

Completed

Bioequivalence Study of V0057 Versus a Reference Formulation After Single Administration in Healthy Male Subjects

Healthy Volunteers

Germany
Pierre Fabre Medicament

Completed

Nicotine Patch Bioequivalence Study

Healthy Smokers

France
Pierre Fabre Medicament

Completed

Nicotine Patch - Multidose Bioequivalence Study

Healthy Smokers

France
Pierre Fabre Medicament

Completed

Pilot Pharmacokinetic Study of New Nicotine Lozenge Formulations

Healthy Smokers

France
Pierre Fabre Medicament

Not yet recruiting

Treatment Patterns of Neratinib in HER2+ EBC in China

Breast Cancer

China
Pierre Fabre Medicament

Terminated

First-In-Human (FIH) Study of W0180 as Single Agent and in Combination With Pembrolizumab in Adults With Locally Advanced or Metastatic Solid Tumors

Locally Advanced or Metastatic Solid Tumors

France, Spain
Pierre Fabre Medicament

Active, not recruiting

Phase II Study Investigating the Combination of Encorafenib and Binimetinib in BRAF V600E Mutated Chinese Patients With Metastatic Non-Small Cell Lung Cancer (OCEANII)

Non-Small Cell Lung Cancer

China, Taiwan
Pierre Fabre Medicament

Completed

Trial of Vinflunine Plus Capecitabine in Advanced Breast Cancer

Breast Cancer

France, Poland, Ukraine, United Kingdom, Taiwan, Spain, Belgium, Belarus, Mexico, Bulgaria, India, South Africa, Brazil, Russian Federation, Argentina, Hungary, Italy, Serbia, Switzerland, Czechia, Estonia
Pierre Fabre Medicament

Completed

Phase III Study of Vinflunine Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer

Malignant Neoplasm of Breast

China, Taiwan, Singapore
Pierre Fabre Medicament

Completed

Phase III Study of Vinflunine Plus Methotrexate Versus Methotrexate Alone in Patients With Head and Neck Cancer

Recurrent or Metastatic Head and Neck Carcinoma

France
Pierre Fabre Dermatology

Withdrawn

Bioavailability Pilot Study of Versus W0035 Versus Stromectol

Healthy Volunteers

United Kingdom
Pierre Fabre Dermatology

Completed

Study to Demonstrate the Efficacy and Safety of Propranolol Oral Solution in Infants With Proliferating Infantile Hemangiomas Requiring Systemic Therapy

Infantile Hemangioma

Germany, United States, France, Spain, Peru, Australia, Lithuania, Italy, Canada, Czech Republic, Hungary, Mexico, New Zealand, Poland, Romania, Russian Federation
Pierre Fabre Medicament

Completed

Nicotine Patch - Bioequivalence Study

Healthy Smokers

France
Pierre Fabre Medicament

Completed

Emollients in the Management of Atopic Dermatitis

Atopic Dermatitis

France, Romania, Estonia, Poland, Lithuania
Pierre Fabre Medicament

Completed

Exploratory Study of L.S.E.S.r. (LipidoSterolic Extract of Serenoa Repens)(PERMIXON® 160 mg Hard Capsule) Versus Tamsulosine LP Activity on Inflammation Biomarkers in Urinary Symptoms Related to BPH (Benign Prostatic Hyperplasia) (PERMIN)

Benign Prostatic Hyperplasia (BPH)

France, Spain, Portugal, Italy
Pierre Fabre Medicament

Completed

FMS European Long-Term Study

Fibromyalgia Syndrome

Spain, Italy, Portugal, France, Czech Republic, Finland, Germany, Norway, Romania, Sweden
Pierre Fabre Medicament

Completed

Efficacy Emollient on Xerosis in Children With Atopic Dermatitis

Atopic Dermatitis

Estonia, France, Lithuania, Poland, Romania
Pierre Fabre Medicament

Withdrawn

Hepatic Impairment Study of Encorafenib in Combination With Binimetinib in BRAF Melanoma

Hepatic Impairment | Metastatic Melanoma | Unresectable Melanoma | BRAF V600 Mutation

Spain, Czechia, Italy
Pierre Fabre Medicament

Completed

Phase 1 Safety Study of Encorafenib in Chinese Patients With Advanced Metastatic BRAF V600E Mutant Solid Tumors (OCEANI)

Melanoma | BRAF V600E Unresectable or Metastatic Melanoma | BRAF V600E Metastatic NSCLC

China
Pierre Fabre Medicament

Terminated

A Study of Vinflunine Plus Gemcitabine Versus Paclitaxel Plus Gemcitabine in Patients With Advanced Breast Cancer (VICTORIA)

Advanced Breast Cancer
Pierre Fabre Medicament

Completed

F17464 in Acute Schizophrenia Trial (FAST)

Schizophrenia

Romania, Russian Federation, Hungary, Latvia, France
Pierre Fabre Medicament

Completed

Efficacy on Volume Reduction and Tolerance of Progressiv' Medical Compressive Therapy (MCT) V0322 BC in Patients With Chronic Venous Oedema

Chronic Venous Insufficiency (CVI)

France
Pierre Fabre Medicament

Completed

Effect of F2695 on Brain Activity Measured by Functional Magnetic Resonance Imaging

Subject

France
Pierre Fabre Medicament

Completed

PERmixon® in LUTS Evaluation Study (PERLES) (PERLES)

Benign Prostatic Hyperplasia (BPH)

France, Italy, Germany, Spain, Czech Republic
Pierre Fabre Medicament

Completed

Efficacy of 0.2 % Digluconate Chlorhexidine Mouthwash for Preventing Alveolar Osteitis After Third Molar Extraction

Alveolar Osteitis

France, Lithuania, Latvia, Estonia

Clinical Trials Sponsored by Pierre Fabre Laboratories

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Türkiye

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations